Therapeutic strategies for advanced respectable esophageal cancer

研究成果: Article

5 引用 (Scopus)

抄録

There are obvious differences in the clinical characteristics of patients with advanced respectable esophageal cancer between Japan and Western countries. In Japan, more than 90% of patients with esophageal cancer are histologically diagnosed with squamous cell carcinoma. On the other hand, the incidence of esophageal adenocarcinoma is rapidly increasing in the West. As a standard surgical approach, relatively invasive transthoracic extended esophagectomy has been established in Japan since the 1980s and has contributed to improved long-term survival of patients with squamous cell carcinoma. The current standard care for resectable stage II/III esophageal squamous cell carcinoma is neoadjuvant chemotherapy with 5-fluorouracil/cisplatin and radical esophagectomy based on the results of Japan Clinical Oncology Group trial 9907. In the West, relatively less invasive transhiatal esophagectomy with limited lymph node dissection has played a role in the multidisciplinary treatment of esophageal adenocarcinoma. Recently, a multimodal approach to esophageal cancer treatment including definitive chemoradiotherapy has been a focus of attention in both Japan and the West. For the further improvement of long-term survival of patients with esophageal cancer, the optimization of multimodal treatments and establishment of a global standard are essential.

元の言語English
ページ(範囲)333-337
ページ数5
ジャーナルNippon Geka Gakkai zasshi
109
発行部数6
出版物ステータスPublished - 2008 11

Fingerprint

Esophageal Neoplasms
Japan
Esophagectomy
Squamous Cell Carcinoma
Adenocarcinoma
Therapeutics
Combined Modality Therapy
Survival
Medical Oncology
Chemoradiotherapy
Lymph Node Excision
Fluorouracil
Cisplatin
Drug Therapy
Incidence

ASJC Scopus subject areas

  • Medicine(all)

これを引用

Therapeutic strategies for advanced respectable esophageal cancer. / Kitagawa, Yuukou.

:: Nippon Geka Gakkai zasshi, 巻 109, 番号 6, 11.2008, p. 333-337.

研究成果: Article

@article{2f7c50ecc1724f418dabe831d255abd7,
title = "Therapeutic strategies for advanced respectable esophageal cancer",
abstract = "There are obvious differences in the clinical characteristics of patients with advanced respectable esophageal cancer between Japan and Western countries. In Japan, more than 90{\%} of patients with esophageal cancer are histologically diagnosed with squamous cell carcinoma. On the other hand, the incidence of esophageal adenocarcinoma is rapidly increasing in the West. As a standard surgical approach, relatively invasive transthoracic extended esophagectomy has been established in Japan since the 1980s and has contributed to improved long-term survival of patients with squamous cell carcinoma. The current standard care for resectable stage II/III esophageal squamous cell carcinoma is neoadjuvant chemotherapy with 5-fluorouracil/cisplatin and radical esophagectomy based on the results of Japan Clinical Oncology Group trial 9907. In the West, relatively less invasive transhiatal esophagectomy with limited lymph node dissection has played a role in the multidisciplinary treatment of esophageal adenocarcinoma. Recently, a multimodal approach to esophageal cancer treatment including definitive chemoradiotherapy has been a focus of attention in both Japan and the West. For the further improvement of long-term survival of patients with esophageal cancer, the optimization of multimodal treatments and establishment of a global standard are essential.",
author = "Yuukou Kitagawa",
year = "2008",
month = "11",
language = "English",
volume = "109",
pages = "333--337",
journal = "Nihon Geka Gakkai zasshi",
issn = "0301-4894",
publisher = "Nihon Geka Gakkai",
number = "6",

}

TY - JOUR

T1 - Therapeutic strategies for advanced respectable esophageal cancer

AU - Kitagawa, Yuukou

PY - 2008/11

Y1 - 2008/11

N2 - There are obvious differences in the clinical characteristics of patients with advanced respectable esophageal cancer between Japan and Western countries. In Japan, more than 90% of patients with esophageal cancer are histologically diagnosed with squamous cell carcinoma. On the other hand, the incidence of esophageal adenocarcinoma is rapidly increasing in the West. As a standard surgical approach, relatively invasive transthoracic extended esophagectomy has been established in Japan since the 1980s and has contributed to improved long-term survival of patients with squamous cell carcinoma. The current standard care for resectable stage II/III esophageal squamous cell carcinoma is neoadjuvant chemotherapy with 5-fluorouracil/cisplatin and radical esophagectomy based on the results of Japan Clinical Oncology Group trial 9907. In the West, relatively less invasive transhiatal esophagectomy with limited lymph node dissection has played a role in the multidisciplinary treatment of esophageal adenocarcinoma. Recently, a multimodal approach to esophageal cancer treatment including definitive chemoradiotherapy has been a focus of attention in both Japan and the West. For the further improvement of long-term survival of patients with esophageal cancer, the optimization of multimodal treatments and establishment of a global standard are essential.

AB - There are obvious differences in the clinical characteristics of patients with advanced respectable esophageal cancer between Japan and Western countries. In Japan, more than 90% of patients with esophageal cancer are histologically diagnosed with squamous cell carcinoma. On the other hand, the incidence of esophageal adenocarcinoma is rapidly increasing in the West. As a standard surgical approach, relatively invasive transthoracic extended esophagectomy has been established in Japan since the 1980s and has contributed to improved long-term survival of patients with squamous cell carcinoma. The current standard care for resectable stage II/III esophageal squamous cell carcinoma is neoadjuvant chemotherapy with 5-fluorouracil/cisplatin and radical esophagectomy based on the results of Japan Clinical Oncology Group trial 9907. In the West, relatively less invasive transhiatal esophagectomy with limited lymph node dissection has played a role in the multidisciplinary treatment of esophageal adenocarcinoma. Recently, a multimodal approach to esophageal cancer treatment including definitive chemoradiotherapy has been a focus of attention in both Japan and the West. For the further improvement of long-term survival of patients with esophageal cancer, the optimization of multimodal treatments and establishment of a global standard are essential.

UR - http://www.scopus.com/inward/record.url?scp=58149382612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149382612&partnerID=8YFLogxK

M3 - Article

C2 - 19068714

AN - SCOPUS:58149382612

VL - 109

SP - 333

EP - 337

JO - Nihon Geka Gakkai zasshi

JF - Nihon Geka Gakkai zasshi

SN - 0301-4894

IS - 6

ER -